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The prevention of obesity and health concerns related to body fat is a major challenge worldwide. The aim of this study was
to investigate the role of a medically supervised, multidisciplinary approach, on reduction in the prevalence of obesity related
comorbidities, inflammatory profile, and neuroendocrine regulation of energy balance in a sample of obese adolescents. A total of
97 postpuberty obese adolescents were enrolled in this study. Body composition, neuropeptides, and adipokines were analysed.The
metabolic syndrome was defined by the International Diabetes Federation (IDF). The abdominal ultrasonography was performed
to measure visceral, subcutaneous fat and hepatic steatosis. All measures were performed at baseline and after one year of
therapy. The multidisciplinary management promoted the control of obesity reducing body fat mass. The prevalence of metabolic
syndrome, asthma, nonalcoholic fatty liver disease (NAFLD), binge eating, and hyperleptinemia was reduced. An improvement in
the inflammatory profile was demonstrated by an increase in anti-inflammatory adiponectin and reduction in proinflammatory
adipokines, plasminogen activator inhibitor-1, interleukin-6 concentrations, and in the Lep/Adipo ratio. Moreover, a reduction
in the AgRP and an increase in the alfa-MSH were noted. The multidisciplinary approach not only reduced obesity but also is
efficacious in cardiovascular risk factors, inflammatory profile, and neuroendocrine regulation of energy balance.
1. Introduction
The prevalence of overweight and obesity has increased in
many low- and middle-income countries [1]. It is estimated
that 50% of the adult Brazilian population is overweight, with
an obesity rate of 12.5% and 16.9% for men and women,
respectively [2]. Similar trends were observed in adolescents,
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whereby 21% present some degree of overweight and obesity.
Previously, it has been showed that obese adolescents present
a high degree of nonalcoholic fatty liver disease (NAFLD),
metabolic syndrome, asthma, binge eating symptoms, dis-
ruption in the neuroendocrine regulation of energy balance,
and other impairments, reducing the effectiveness of weight
management [3–9].
In obese Brazilian adolescents it was observed that 27.16%
present diagnoses ofmetabolic syndrome (MS).Themost fre-
quently altered parameter was HOMA-IR [4, 10]. This result
suggests a heightened pro/inflammatory state, considering
that insulin resistance (IR) is an independent predictor of
alterations in the carotid intima-media thickness (IMTc), a
subclinical surround of atherosclerosis in obese adolescents
[11].
Obesity is a multifactor disease, resulting mainly from
sedentary behaviours coupled with inadequate eating habits
[12, 13]. Researchers worldwide have been searching for the
best strategy to combat obesity [14–16]. Recent data supports
the short-term effectiveness and clinical utility of using the
interdisciplinary model. Moreover, a multicentre evaluation
of an interdisciplinary weight loss program for obesity
showed that this kind of intervention is highly effective, not
only in obesity but for other related disorders. This data
suggests the importance of this type of therapy as a strategy
required for sustained success of long-term life treatment
[16]. Furthermore, the importance of parenting in the effec-
tiveness of the treatment and the prevention of behaviour
problems in the control of obesity and health disorders in
children and adolescents was recently demonstrated [17].
The overall result of a multifaceted obesity-management
program, addressed by usingmultidisciplinary teams, in local
and international literature is limited. The purpose of this
study was to analyse the effects of a one-year weight loss
approach on the control of obesity and related comorbidi-
ties, including metabolic profile, inflammatory markers, and
neuroendocrine regulation of energy balance on a sample of
obese adolescents within a medically supervised multidisci-
plinary obesity-management program.
2. Material and Methods
2.1. Conceptual Design of Interdisciplinary Obesity Manage-
ment. Taking into consideration the multfactorial charac-
teristics of obesity, a multidisciplinary therapy program was
developed with the twin aims of combating the main trigger
factors of obesity and increasing adherence to, as well as
improving responses to, the treatment (Figure 1).
2.2. Sample. For this study, a sample of 97 postpuberty obese
adolescents (56 girls and 41 boys) was engaged, with ages
of 15–19 years, and the sampling method was a consecutive
selection of the sample. The study was announced in the
media on TV and radio and in journals and the adolescents
were selected according to the inclusion and exclusion criteria
of the study. The adolescents of this study had the same
level of education and mainly belonged to the same social
class and ethnicity. These adolescents were recruited from
Sa˜o Paulo, Brazil, and the program ran from January to
December during three consecutive years.
Inclusion criteria were tanner stage five [18], primary
obesity, and body mass index (BMI) greater than 30 kg/m2
(BMI > 95th percentile of the CDC reference growth charts).
Exclusion criteria were age under 14 or over 18 years, the use
of birth control pills, cortisone, antiepileptic drugs, history
of renal disease, alcohol intake, use of tobacco, secondary
obesity due to endocrine disorders, diagnoses of ferritin
alteration, autoimmune diseases, and presence ofHepatitis A,
B and C virus.
Only the adolescents who had compliance of 75% in all
sections of the therapy were included in the analyses. The
main reasons for dropping out (𝑛 = 20) in the present
study were financial and family problems, followed by school
and job opportunities. No sex differences were observed in
adherence rates.The study was conducted with the principles
of the Declaration of Helsinki and was approved by the
ethics committee on research at the Universidade Federal de
Sa˜o Paulo (UNIFESP) with the number 0135/04, Clinical-
Trials.gov NCT01358773. All procedures were made clear to
those responsible for the volunteers and consent for research
was agreed. All evaluations were performed at two different
times (baseline: beginning and end of therapy: after 1 year of
therapy).
2.3. Anthropometric Measurements. Weight was measured
by the plethysmography scale (BODPOD equipment) where
patients wore the minimum clothing possible and height was
measured using a stadiometer (Sanny, model ES 2030). After
obtaining the data, body mass index (BMI) was calculated
by dividing the weight by height squared (kg/m2). Body
composition, including body fat (percentage and kilograms)
and lean mass (percentage and kilograms), was obtained
through air displacement plethysmography (BODPOD).
2.4. Serum Analysis. Blood samples were collected at the
outpatient clinic at approximately 8:00 a.m. after an overnight
fast (12 hours). Insulin resistance was assessed by the home-
ostasis model assessment insulin resistance index (HOMA-
IR). HOMA-IR was calculated using the FBG and the
immune-reactive insulin (I): (FBG (mg/dL)× I (mU/l))/405.
Triglyceride (TG), HDL, low-density lipoprotein (LDL), and
very-low-density lipoprotein (VLDL) were analysed using a
commercial kit (CELM, Barueri, Brazil).The reference values
were HOMA-IR < 2.0 and insulin < 20𝜇U/mL, as previously
described by Schwimmer et al. [19].
The adipokines concentrations were measured using
commercial immunoassay kits eBioscience (San Diego, CA,
USA) and R&D Systems (Minneapolis, MN, USA) according
to manufacturers’ manual. The reference values for leptin
have been previously described by Gutin et al. [20].
2.5. Hepatic Steatosis, Visceral and Subcutaneous Adiposity
Measurements. The abdominal ultrasonography (US) proce-
dures and the measurements of visceral and subcutaneous fat
tissue and fatty liver were performed by the same physician
at the baseline time point and following 1 year of therapy.
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Figure 1: Design conception of interdisciplinary therapy on obesity management in adolescents.
This physician was a specialist in imaging diagnostics. A
3.5-MHz multifrequency transducer (broad band) was used
to reduce the risk of misclassification. The intraexamination
coefficient of the variation for abdominal US was 0.8%. US
measurements of intra-abdominal (visceral) and subcuta-
neous fat were obtained. US-determined subcutaneous fat
was defined as the distance between the skin and external
face of the rectus abdominal muscle, and visceral fat was
defined as the distance between the internal face of the same
muscle and the anterior wall of the aorta. The cut-off points
for the definition of visceral obesity by ultrasonography were
based on the previous methodological descriptions [21]. In a
previous study, it was found that US seemed to be the best
alternative method for the assessment of intra-abdominal fat
in obese women. US correlated positively with computed
tomography (CT). A value of 6.90 cm for visceral fat US
determined diagnosed visceral obesity with a specificity of
82.8%, a sensitivity of 69.2%, and a diagnostic concordance
of 74% with CT [21].
Steatosis evaluation was performed by abdominal ultra-
sonography. The definition of ultrasonic fatty liver was based
on previously reported diagnostic criteria and detected liver
steatosiswas classified as grade 1 (liver attenuation slightly less
than spleen); grade 2 (more pronounced difference between
liver and spleen and intrahepatic vessels not seen or slightly
higher attenuation than liver); grade 3 (markedly reduced
liver attenuation with a sharp contrast between liver and
intrahepatic vessels) [22, 23]. In this study, the group with
NAFLD presented some liver steatosis grade diagnosed by
abdominal US.
2.6. Clinical Intervention
2.6.1. Medical Monitoring. Adolescents underwent a diag-
nostic clinical evaluation for general health (family his-
tory and obesity) and sexual maturation was also assessed.
Subsequently, adolescents were examined monthly. Meta-
bolic syndrome was defined using International Diabetes
Federation criteria: a waist circumference (WC) greater
than 80 cm for girls and 94 cm for boys, high-density
lipoprotein (HDL) values ≤50mg/dL for girls and ≤40mg/dL
for boys, concentrations of triglycerides (TG) higher than
150mg/dL, blood glucose levels higher than 100mg/dL, and
blood pressures≥130/85mmHg [24].Thediagnosis of asthma
was made according to ATS guidelines [25].
2.6.2. Physical Intervention. During the intervention (1 year),
adolescents followed a program of combined training (aero-
bic/resistance exercise) which included sessions of 60 min-
utes (30min aerobic and 30min resistance) with a frequency
of three times a week (180 minutes/week), under the supervi-
sion of an exercise physiologist.The aerobic training program
was established based on a cardiopulmonary exercise test.The
intensity of aerobic training was fixed at the load correspond-
ing to the first ventilatory threshold (50%–70% of oxygen
consumption test). During every session of aerobic exercise,
heart rate was monitored by a frequency counter. Resistance
training was divided into two types, wave (with loads of
repeats 15–20, 10–12 and 6–8) and linear (20 replicates), based
on exercises that covered large muscle groups of both lower
and upper limbs. The program follows the recommendations
given by the American College of Sports Medicine [26].
2.6.3. Nutritional Intervention. Food consumption was set at
the recommended levels of dietary intake for individuals with
low levels of physical activity, based on age, gender, and a
balanced diet [27]. No medication or types of supplements
were recommended. Once a week, the adolescents had classes
on topics related to improved food consumption and they
all received individual consultations during the intervention
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Figure 2: Methodological description.
program. At the beginning and after the long-term multidis-
ciplinary therapy, each adolescent filled in a three-day dietary
record with the help of his/her parents. These dietary data
were transferred to a computer by the same nutritionist, and
the nutrient composition was analysed by a PC program
developed at the Universidade Federal de Sa˜o Paulo, Escola
Paulista de Medicina (Nutwin software, for Windows, 1.5
version, 2002)—based on Western and local food tables.
The caloric content was estimated using Dietary Refer-
ence Intakes equations, according to low levels of physical
activity, based on age and patient gender. The distribution
of macronutrients was fat (25–35%), carbohydrate (45–65%),
and protein (10–30%). It is important to highlight that food
quality was also assessed during nutrition intervention [27,
28].
2.6.4. Psychological Intervention. Diagnoses of psychological
problems most commonly associated with obesity, such as
depression, body image concerns, anxiety, and lower self-
esteem, were assessed through validated questionnaires. Dur-
ing long-term intervention, adolescents were followed up
weekly in the one year therapy support group, and if nec-
essary, individual psychological therapy was recommended
when behavioural alterations were found (data not shown).
During psychological therapy, all adolescents completed
the Portuguese versions of the BES to verify the symptoms of
binge eating and BITE to verify Bulimia symptoms, including
the purgative subtype (Figure 2) [29, 30].
2.6.5. Statistical Analysis. The data are presented as the
mean± standard deviation (SD), and 𝑃 ≤ 0.05 was con-
sidered statistically significant. Distributional assumptions
were verified using the Kolmogorov-Smirnov test, and non-
parametric methods were performed where appropriate.
Adipokines levels were analysed using parametric tests
and were expressed as mean± SD unless otherwise stated.
Comparisons between the baseline measurements and the
measurements after the weight-loss therapy were made using
the paired student’s 𝑡-test or the Wilcoxon signed rank
test for nonparametric variables. The prevalence of obesity
complications was demonstrated by the frequency table
and applied chi-square test (McNemar) analysis. Correlation
analysis between the variables was performed using Pearson’s
correlation test. The delta variation (Δ) was used for the
statistical analysis obtained from the difference between the
baseline and final values for each variable. All of the analyses
were computed using STATISTICA version 6 for Windows.
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Figure 3: Prevalence of obesity complications: (a) metabolic syndrome factors; (b) comorbidities associated with obesity; ∗statistical
significance, 𝑃 < 0.05.
3. Results
3.1. Effects of Therapy on the Prevalence of Related Comorbidi-
ties. The interdisciplinary management promoted obesity
control, reducing the prevalence of metabolic syndrome,
nonalcoholic fatty liver diseases, asthma, insulin resistance,
and eating disorders, including symptoms of bulimia nervosa
and binge eating disorder (Table 1; Figures 3(a)-3(b)).
3.2. Effects ofTherapy on Body Composition, Visceral and Sub-
cutaneous Fat and Metabolic Profile. A significant reduction
in the body mass, fat mass, visceral fat, subcutaneous fat,
waist circumference, and blood pressure was shown. These
data were associated with an increased fat free mass, demon-
strating an improvement inmost risks related to obesity, after
one year of interdisciplinary therapy (Table 2). However, it
is important to state that only one obese adolescent reached
the reference values of body fat mass after therapy, according
to the Paediatric Brazilian Association [31].
Other important results observed in the present study
were the statistical reduction in insulin, triglyceride, LDL,
and VLDL cholesterol concentrations. On the other hand,
HDL concentration and insulin resistance index (HOMA-IR)
were improved (Table 3). However, the glucose concentration
did not change the values remaining in the normal concen-
tration.
3.3. Effects ofTherapy on theMarkers of Neuroendocrine Regu-
lation of Energy Balance. In addition, the weight loss therapy
promoted an improvement in themarkers of neuroendocrine
regulation of energy balance, including a significant reduc-
tion in the orexigenic factor AgRP, as well as an increase
in the anorexigenic factor 𝛼-MSH. However, no significant
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Table 1: Prevalence of metabolic disorders associated with obesity.
Variables Baseline (%) After therapy (%) 𝑃 value
Metabolic syndrome
factors (IDF classification)
Glucose 13 5 <0.001
Insulin 23 4 <0.001
Triglyceride 17 7 <0.001
HDL-cholesterol 42 31 0.30
Systolic blood pressure 26 5 <0.001
Diastolic blood pressure 14 2 <0.001
Waist circumference 62 14 <0.001
MS
NAFLD
Metabolic syndrome 30 2 <0.001
Nonalcoholic fatty liver disease 33 10 <0.001
Others complications
HOMA-IR 83 40 <0.001
Hyperleptinemia 75 55 <0.001
Asthma 16 0 <0.001
Binge eating 6 2 <0.001
Statistical significance 𝑃 ≤ 0.05; HOMA-IR: homeostasis model assessment insulin-index resistance; HLD: high-density lipoprotein; IDF: International
Diabetes Federation; MS: metabolic syndrome; NAFLD: nonalcoholic fatty liver disease.
Table 2: Effects of interdisciplinary therapy in body composition.
Variables Baseline After therapy 𝑃 value Δ value
Body mass (kg) 106.2 ± 16.2 94.4 ± 16.9 <0.001 −11.1 ± 7.7
Height (m) 1.68 ± 0.08 1.69 ± 0.08 0.07 0.009 ± 0.01
BMI (kg/m2) 37.0 ± 4.95 32.9 ± 5.32 <0.001 −4.27 ± 2.82
Fat mass (kg) 49.72 ± 11.66 36.5 ± 11.9 <0.001 −13.23 ± 7.02
Fat mass (%) 46.8 ± 5.70 38.0 ± 7.7 <0.001 −8.56 ± 4.58
Free fat mass (kg) 54.7 ± 10.4 57.0 ± 11.9 <0.001 2.24 ± 4.29
Free fat mass (%) 53.1 ± 5.7 61.9 ± 7.7 <0.001 8.74 ± 4.84
Visceral fat (cm) 4.5 ± 1.5 2.8 ± 1.3 <0.001 −1.60 ± 1.13
Subcutaneous fat (cm) 4.1 ± 0.8 3.2 ± 0.8 <0.001 −0.84 ± 0.80
Waist circumference (cm) 103.4 ± 10.7 94.9 ± 11.6 <0.001 −9.5 ± 18.32
Systolic blood pressure (mmHg)∗ 120 (100–190) 110 (100–140) <0.001 −10.00 (−70–20)
Diastolic blood pressure (mmHg)∗ 80 (70–110) 70 (60–90) <0.001 0.00 (−40–10)
∗Nonparametric data; BMI: body mass index; statistical significance 𝑃 ≤ 0.05.
Table 3: Effects of interdisciplinary therapy in metabolic profile (factors associated with metabolic syndrome definition by International
Diabetes Federation (IDF)).
Variables Baseline After therapy 𝑃 value Δ value
Waist circumference (cm) 103.4 ± 10.7 94.4 ± 11.6 <0.001 −9.5 ± 18.32
Glucose (mg/dL) 90.5 ± 7.8 89.7 ± 7.7 0.43 0.77 ± 8.60
Insulin (𝜇U/mL) 17.1 ± 8.0 12.0 ± 9.6 <0.001 −4.94 ± 10.50
HDL-cholesterol (mg/dL) 43.7 ± 8.6 45.3 ± 9.2 <0.001 1.80 ± 5.51
LDL-cholesterol (mg/dL) 102.4 ± 27.4 94.0 ± 24.0 <0.001 −9.98 ± 17.54
VLDL-cholesterol (mg/dL) 21.3 ± 9.4 17.8 ± 8.5 <0.001 −3.44 ± 8.06
Triglyceride (mg/dL) 111.2 ± 64.2 88.9 ± 42.6 <0.001 −21.27 ± 52.50
HOMA-IR 3.8 ± 2.0 2.7 ± 1.7 <0.001 −1.13 ± 3.00
HOMA-IR: homeostasis model assessment insulin-index resistance; HLD: high-density lipoprotein; LDL: low-density lipoprotein; VLDL: very-low-density
lipoprotein. Reference values: glucose (60–110mg/dL); insulin (<20 𝜇U/mL); HOMA-IR (<2.0); total cholesterol (<170mg/dL); Triglyceride (33–129mg/dL);
HDL cholesterol (>38mg/dL); LDL cholesterol (<130mg/dL); VLDL cholesterol (10–50mg/dL) (2); statistical significance 𝑃 ≤ 0.05.
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Table 4: Effects of interdisciplinary therapy in neuroendocrine regulation of energy balance and inflammatory profile.
Variables Baseline After therapy 𝑃 value Δ value
Neuroendocrine regulation of energy balance
AgRP (ng/mL) 0.76 ± 1.45 0.55 ± 0.34 <0.001 0.05 ± 0.14
NPY (ng/mL) 1.42 ± 1.75 1.55 ± 2.28 0.66 0.14 ± 2.82
NPY/AgRP ratio∗ 0.41 (0.03–9.1) 0.42 (0.01–5.33) 0.07 0.02 (−2.47–2.86)
MCH (ng/mL) 4.14 ± 2.42 4.95 ± 2.50 0.80 0.45 ± 1.81
𝛼-MSH (ng/mL) 0.99 ± 0.54 1.06 ± 0.75 0.03 0.10 ± 0.44
Ghrelin (ng/mL) 1.10 ± 0.27 1.14 ± 0.24 0.40 0.02 ± 0.17
Leptin (ng/mL) 42.59 ± 26.62 27.41 ± 20.48 <0.001 −19.77 ± 25.32
Inflammatory profile
Adiponectin (𝜇g/L) 6.61 ± 3.61 7.42 ± 4.61 <0.001 1.63 ± 2.69
Lep/Adipo ratio∗ 5.7 (0.15–44.3) 3.7 (0.16–30.9) <0.001 −10.48 (5.64–36.41)
TNF-𝛼 (ng/mL) 44.31 ± 78.9 29.25 ± 41.45 0.23 −15.05 ± 52.03
CRP (ng/mL) 6.38 ± 11.34 8.75 ± 14.87 0.48 1.82 ± 17.36
Resistin (ng/mL) 12.45 ± 10.5 13.10 ± 10.3 0.71 0.22 ± 4.88
PAI-1 (ng/mL) 13.4 ± 8.1 9.6 ± 8.3 <0.001 −3.94 ± 6.00
interleukin-6 (IL-6) 58.3 ± 46.9 32.4 ± 21.7 0.05 −25.88 ± 49.85
∗Nonparametric data; statistical significance 𝑃 ≤ 0.05; AgRP: Agouti-related peptide; NPY: neuropeptide Y; MCH: melanin-concentrating hormones; 𝛼-
MSH: 𝛼-melanocyte-stimulating hormone; Lep/Adipo ratio: leptin/adiponectin ratio; TNF-𝛼: tumor necrosis factor-alpha; CRP: C-reactive protein; PAI-1:
plasminogen activator inhibitor-1. Reference values: Leptin values between 1 and 20 ng/ml for males and between 4.9 and 24 ng/ml for females.
Table 5: Correlations analysis.
Variables (Δ values) 𝑅 value 𝑃 value
Fat mass (kg)
Free fat mass (%) −0.75 0.001
Adiponectin (𝜇g/L) −0.72 0.001
Lep/Adipo ratio 0.67 0.003
Visceral fat (cm) −0.57 0.871
Subcutaneous fat (cm) Fat mass (%) 0.71 0.002
Free fat mass (%) −0.71 0.002
Adiponectin (𝜇g/L)
Body mass (kg) −0.65 0.003
Visceral fat (cm) −0.20 0.571
HOMA-IR −0.20 0.873
PAI-1 (ng/mL) Ghrelin (ng/mL) 0.68 0.002
Visceral fat (cm) HOMA-IR 0.67 0.572
Fat mass (%) −0.28 0.421
Lep/Adipo ratio: leptin/adiponectin ratio; PAI-1: plasminogen activator inhibitor-1; HOMA-IR: homeostasis model assessment insulin index-resistance;
statistical significance 𝑃 ≤ 0.05.
changes in the NPY, MCH, and ghrelin concentrations and
NPY/AgRP ratio were observed (Table 4).
3.4. Effects of Therapy on the Inflammatory Markers. The
inflammatory profile was improved as demonstrated by
an increase in the concentration of anti-inflammatory
adipokine adiponectin, and a reduction in the proinflamma-
tory adipokines, including plasminogen activator inhibitor-
1 and interleukin-6 concentrations. Moreover, the hyper-
leptinemia was reduced and leptin/adiponectin ratio was
improved. However, no changes in TNF-alpha, CRP, and
resistin concentrations were observed (Table 4).
3.5. Correlation Analysis. Finally, in the correlation analysis
of the delta values (Δ) a positive correlation between fat mass
with Lep/Adipo; subcutaneous fat with fatmass; plasminogen
activator inhibitor-1 with ghrelin was observed. Conversely,
negative correlations were observed between fat mass with
fat free mass and adiponectin; subcutaneous fat with fat free
mass; adiponectin with body mass (Table 5).
4. Discussion
The prevention of obesity and health concerns related to
excessive body fat are major challenges worldwide, especially
considering the effect of childhood and adolescent obesity
on our productive population in the near future. Therefore,
using a holistic approach and multidisciplinary therapies,
addressing related risk factors including a reduction in the
prevalence of metabolic syndrome (MS), nonalcoholic fatty
liver disease (NAFLD), asthma, and dyslipidemia whilst
promoting improved quality of life and health, is valid.
Corroborating, data using the IDF criteria showed that
70% of obese women had diagnosis to MS. Moreover,
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an alarming prevalence of MS in childhood was found,
suggesting therefore a focus on primary prevention and the
promotion of healthy lifestyles. In addition, it was suggested
that diet, exercise training, andweight loss provide significant
clinical benefits and must be considered as the first line
for treating both NAFLD and MS. Together, these results
highlight the importance of multidisciplinary approach in
early life [32–34].
In fact, MS and NAFLD have been implicated in both
disruption of neuroendocrine regulation of energy balance
and accentuated inflammatory process, which may impair
the benefits of weight loss therapy [6, 10, 35]. Therefore,
an important finding corroborating this hypothesis is that
the balance between orexigenic and anorexigenic factors
was improved, since a reduction in AgRP and increase in
the alfa-MSH were observed in the present study. This was
probably modulated by a significant reduction in the state of
hyperleptinemia, a key hormone implicated in the central and
peripheral control of energy balance [9].
Moreover, a reduction of 27% of body fat, a significant
reduction in visceral fat, subcutaneous fat, waist circum-
ference, and an increase in the free fat mass was observed
(Table 2). In support of this we showed a negative correlation
between delta values of fat mass with free fat mass (𝑅 =
−0.75, 𝑃 = 0.001) (Table 5). Fujioka et al. showed that
the decrease in the visceral/subcutaneous ratio and visceral
fat was strongly correlated with the improvement in plasma
glucose and lipid metabolism [36]. Furthermore, Lee et al.
showed that a reduction in body fat had significant effects on
metabolic diseases, including cardiovascular disorders.Thus,
this significant reduction in fat mass improves not only life
expectancy but also significantly reduces the public sector
costs associated with obesity related diseases [37, 38]. In
addition, it is important to note that insulin resistance was
decreased significantly in the study group (Table 3); however,
the comparison between genders showed that the therapy
was more effective to reduce insulin and HOMA-IR in males
compared with female adolescents. However, the values of
insulin and HOMA-IR were higher in male compared with
female (data not shown).
On the other hand, the NPY and MCH were not
improved. This may have occurred as a result of the per-
centage of weight loss (approximately 12% of their body
mass), suggesting that these neuropeptides require a massive
weight loss to favour changes in concentrations and improve
the energy balance. In fact, it was shown previously in
another study with obese adolescents that in the beginning
of weight loss therapy the NPY concentration was increased
as a compensatory adaptation and after a massive weight loss
the NPY returns to basal values [39]. The second hypothesis
is that in this analysis, the ghrelin concentration was not
changed, with the role of this orexigenic hormone in the
upregulation of NPY being well established.
Moreover, the neuroendocrine regulation of energy bal-
ance is influenced by PAI-1, since it was demonstrated that
this prothrombotic adipokine is involved in the response of
NPY concentration in obese adolescents [35]. This was con-
firmed in the present investigation by a positive correlation
between delta values of PAI-1 with ghrelin concentration
(𝑅 = 0.68; 𝑃 = 0.002) (Table 5). Thus, another important
finding in the present investigation was a reduction in PAI-
1 and interleukin-6. Supporting this result, the adiponectin
was significantly increased, favouring amelioration in the
Lep/Adipo ratio, improving the control of subclinical inflam-
mation, commonly associated with obesity.
The adiponectin concentration is a potent anti-inflam-
matory adipokine and acts in the regulation of insulin
homeostasis, favouring the control of many chronic diseases,
including atherosclerosis, hypertension, NAFLD, metabolic
syndrome, cardiovascular diseases, thrombosis, and asthma
[6, 7, 11, 40]. These data reinforce the importance of the
results observed in the present study, mainly the reduction
of hyperleptinemia and the increase in the adiponectinemia,
promoting the decrease in the Lep/Adipo ratio. In addition,
we showed a positive correlation between delta values of
Lep/Adipo with fat mass and negative correlation between
adiponectin with body mass and fat mass (Table 5).
Previously, it was shown that massive weight loss pro-
moted an increase in adiponectin and adiponectin/leptin
(A/L) ratio; additionally, a decrease in leptin levels and a
reduction in exercise induced bronchospasm frequency and
asthma-related symptoms, improving pro/anti-inflammatory
adipokines. Furthermore, the leptin concentration was a
predictor factor to explain changes in lung function, demon-
strating the role of this adipokine in the inflammatory pro-
cess, linking obesity and pulmonary disorders [7]. Therefore,
another significant finding in the present investigation was a
reduction in the prevalence of asthma from 16% to 0%.
Interestingly, states of hyperleptinemia have also been
implicated in the development of atherosclerosis [9]. Sup-
porting this, at the beginning of the intervention, 75% of
the analysed obese adolescents presented a hyperleptinemia
state; after intervention 55% remained in this condition, but
both prevalence and median values of this adipokine were
significantly decreased as mentioned above.
Although there was a significant improvement in the
inflammatory state resulting from leptin reduction, lep-
tin/adiponectin ratio, and increase in adiponectin, others
important inflammatory markers such as TNF-𝛼, resistin,
and CRP were not reduced. A possible explanation could
be the presence of a hyperleptinemia state since 55% of the
adolescents remained with high levels of leptin, even after
significant reduction in concentration, suggesting that the
neuroendocrine systemcould interpose in inflammatory pro-
cess. However the complete understanding of the interplay
between neuroendocrine regulations of energy balance and
inflammation needs to be explored further. Reinforcing this
hypothesis, Corgosinho et al. showed a positive correlation
between PAI-1 and some orexigenic neuropeptides, such as
the NPY, MCH, and the NPY/AgRP ratios suggesting that
the impairment in the control of energy balance acts in a
dependent manner, involving inflammatory processes [35].
Some limitations need to be taken into account in
interpretation of these findings. First, we had a dropout of
20% of the sample. The main reasons for dropping out in
our study were financial and domestic, followed by education
and job opportunities. Secondly, there is no control group
in this study to compare with the normal states of cytokines
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and inflammation markers. Thirdly, a larger sample size is
needed to better confirm the findings. However, the strengths
of the current study include the assessment of a wider range
of obesity comorbidities and parameters in a sample of obese
adolescents undergoing interdisciplinary long-term therapy.
Finally, it is important to observe that obesity is estimated
to reduce average of life expectancy and is imposing a major
economic burden on health insurance [16, 40, 41]. Increasing
physical exercise and decreasing sedentary behaviour are a
worldwide challenge. In fact, an American study aimed to
increase physical activity among Latin adolescents through
a school-based program has proved successful in decreasing
sedentary behaviours. However the study group did not
increase physical activity [42]. Together, the results call
for more initiatives from both public and private health
insurance to challenge not only the control of obesity per se
but also the patterns of altered parameters which may impair
the effect of multidisciplinary strategies in improving health.
5. Conclusion
Themultidisciplinary approach reduced not only obesity but
also the prevalence of metabolic syndrome, NAFLD, asthma,
inflammatory markers, and cardiovascular risk. Moreover,
an improvement in the neuroendocrine regulation of energy
balance was observed. Finally, the design of a type of therapy
that favours better adherence is a challenge, considering the
complexity of this disease and the possibility of increasing
quality and life expectation.
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